FDA AI Device Reporting: Market Growth & Transparency Concerns
- The Food and Drug Administration (FDA) reached a milestone in december, having authorized over 1,000 devices using artificial intelligence (AI) and machine learning (ML).
- Though, in the six months as, even as the federal government considers AI deregulation, the FDA's list of authorized AI/ML devices has remained unchanged. The FDA's regularly-updated list...
- Commissioner marty Makary has been rapid to implement internal AI tools to expedite scientific reviews. However, his plans for regulating AI products, particularly generative AI, remain less clear.
The FDA’s role in regulating AI medical devices faces growing uncertainty. The agency has authorized over 1,000 AI/ML-enabled devices, yet its roadmap for future regulation remains undefined amid federal deregulation efforts. While internal tools expedite scientific reviews, the FDA’s plans for overseeing generative AI are unclear. This evolving landscape of primary_keyword and secondary_keyword regulation sees the FDA’s list of authorized devices static.News directory 3 keeps you ahead of the curve. How will policy decisions shape the future of AI in healthcare? Read this breakdown to understand the complexities. Discover what’s next …
FDA’s Role in AI Device regulation Still Unclear
Updated June 20, 2025
The Food and Drug Administration (FDA) reached a milestone in december, having authorized over 1,000 devices using artificial intelligence (AI) and machine learning (ML). This occurred as the agency finalized regulatory guidelines before President Trump’s inauguration, reflecting the rapid expansion of AI in health care.
Though, in the six months as, even as the federal government considers AI deregulation, the FDA’s list of authorized AI/ML devices has remained unchanged. The FDA’s regularly-updated list reflects the agency’s authorizations.
Commissioner marty Makary has been rapid to implement internal AI tools to expedite scientific reviews. However, his plans for regulating AI products, particularly generative AI, remain less clear. The FDA’s digital health advisory committee previously discussed artificial intelligence.
What’s next
The FDA’s future role in overseeing artificial intelligence and machine learning within the medical device landscape will likely depend on further policy decisions and the evolving understanding of AI’s capabilities and risks.